Definium Therapeutics, Inc.: FMR LLC discloses a stake of more than 5% (Schedule 13G)

FMR LLC disclosed a stake exceeding 5% in Definium Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0000315066-26-002739). The filing signals that the asset manager has crossed the 5% beneficial ownership threshold, a level that typically draws investor attention to a company's shareholder base. Definium Therapeutics is the issuer involved, though the filing did not specify the exact percentage held or the number of shares. The disclosure matters because large institutional positions can influence governance and signal conviction in the stock. Investors will watch for further 13G amendments or 13D filings that could indicate whether FMR's position is passive or activist in nature.